Published in Immunotherapy Weekly, October 24th, 2007
"The clinical efficacy of monoclonal antibodies is generally attributed to target-specific mechanisms resulting from neutralizing or inhibiting a growth factor or receptor that drives cell proliferation and tumor growth. Several targets,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.